Analysis of human cancer tissues has revealed increased GRB2 phosphorylation in high-grade premetastatic tumors, suggesting that pY160 could serve as a potential predictive biomarker in personalized cancer therapy [52]. This evidence concerns the gene GRB2 and cancer.